Serratus anterior plane block (SAPB) and paravertebral block (PVB) are well known to reduce pain levels after video-assisted thoracoscopic surgery (VATS). However, the relative efficacies of each block and a combination of the 2 have not been fully characterized. The objective of the present study was to assess the efficacy of PVB alone, SAPB alone and the combination of PVB and SAPB with regard to the occurrence and intensity of pain after VATS. We conducted the THORACOSOPIC single-centre, double-blind, randomized trial in adult patients due to undergo elective VATS lung resection. The participants were randomized to PVB only, SAPB only and PVB + SAPB groups. The primary end-point was pain on coughing on admission to the postanaesthesia care unit. The secondary end-points were postoperative pain at rest and on coughing at other time points and the cumulative opioid consumption. Pain was scored on a visual analogue scale. One-hundred and fifty-six patients (52 in each group) were included. On admission to the postanaesthesia care unit, the 3 groups did not differ significantly with regard to the pain on coughing: the visual analogue scale score was 3 (0–6), 4 (0–8) and 2 (0–6) in the PVB, SAPB and PVB + SAPB groups, respectively (P =0.204). During postoperative care, the overall pain score was significantly lower in the SABP + PVP group at rest and on cough. The combination of SABP + PVB could be beneficial for pain management in VATS in comparison to SABP or PVB alone.
24 October 2025 in Interdisciplinary CardioVascular and Thoracic Surgery
Objectives: Perioperative veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be used during non-elective thoracic surgery to manage hypoxaemia and facilitate complex surgical procedures. However, outcome data in this setting remain limited, particularly regarding bleeding and thrombotic risks. We aimed to evaluate whether perioperative VV-ECMO during non-elective thoracic surgery is associated with increased 90-day all-cause mortality compared with VV-ECMO used for medical indications, using a propensity score-matched analysis. Secondary outcomes included major bleeding and thrombotic events. Methods: This retrospective bi-centre cohort study included adults treated with VV-ECMO for acute respiratory failure between January 2011 and January 2025 in 2 university intensive care units. Patients were categorized according to ECMO indication: perioperative thoracic surgery or medical. A propensity score was built using multivariable logistic regression, followed by 1:4 nearest-neighbor matching without replacement. The primary endpoint was 90-day mortality; secondary endpoints included major bleeding and thrombotic events. Results: Among 372 patients, 44 (12%) received perioperative VV-ECMO. Ventilator-associated pneumonia (78% vs 57%, P = .01) and haemothorax (36% vs 2%, P < .001) were more frequent in the perioperative group. Ninety-day mortality did not differ between groups, both before (54% vs 51%, P = .71) and after matching (log-rank P = .95). Multivariable Cox analysis confirmed no association between surgical ECMO and mortality (HR = 1.003, 95% CI [0.64-1.57]). No significant differences were found in major bleeding (48% vs 47%, P = 1.00) or thrombotic events (41% vs 32%, P = .31) between groups. Conclusions: Perioperative VV-ECMO during non-elective thoracic surgery was not associated with increased 90-day mortality, bleeding, or thrombotic complications compared to medical VV-ECMO, both before and after matching. These findings support its use in carefully selected patients. Clinical trial registration number: NCT07016685
Objectives: Prolonged air leaks are common after thoracic surgery and may be managed with synthetic aerostatic devices. This study assessed the impact of the Neoveil patch on air leak duration, hospital stay, and postoperative pneumonia. Methods: We conducted a retrospective monocentric study at Amiens University Hospital including adults undergoing lung resection between 2014 and 2024. Patients were divided into three groups: those receiving Neoveil, those not receiving it because of absence of indication, and those operated before its introduction in 2017. For analysis, the two latter groups were pooled as the Non-Neoveil arm. To address confounding, a propensity score was built from baseline covariates with standardized mean difference >5%, and inverse probability weighting was applied. The primary end-point was air leak duration, assessed with weighted linear regression. Secondary outcomes were hospital stay and postoperative pneumonia, analyzed with weighted linear and logistic regression. Results: Among 1216 patients, 313 (26%) received Neoveil. Compared with the control group, Neoveil use was associated with shorter air leak duration both before adjustment (−1.01 days; P = .0004) and after adjustment (−0.67 days; P = .0042). Hospital stay was also reduced (−1.88 days before adjustment; −1.09 days after adjustment; P = .0022). No significant difference was observed for postoperative pneumonia after adjustment (adjusted Odds Ratio 0.73, 95% Confidence Interval 0.48-1.11; P = .14). Conclusions: Neoveil use was associated with reduced air leak duration and shorter hospital stay following lung resection, without significant impact on pneumonia. These findings support its potential role in enhancing postoperative recovery and highlight the need for confirmation in prospective multicentre studies.